Brief: FDA Investigating Serious Risk Of Hematologic Malignancy Following Skysona (Elivaldogene Autotemcel)
27/11/2024 16:33
Nov 27 (Reuters) - FDA:
* FDA INVESTIGATING SERIOUS RISK OF HEMATOLOGIC MALIGNANCY
FOLLOWING SKYSONA (ELIVALDOGENE AUTOTEMCEL)
Further company coverage: BLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on bluebird bio
See all newsBrief: Bluebird Bio Announces Completion Of Acquisition By Carlyle And SK Capital
Brief: Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
Brief: Carlyle, SK Capital Partners And Bluebird Bio Provide Updated Tender Instructions
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Robinhood, Oklo, Chimera Investment